Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Canaccord Genuity Group assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set a "buy" rating and a $106.00 price target on the stock. Canaccord Genuity Group's target price indicates a potential upside of 28.16% from the company's current price.

Several other equities research analysts have also recently commented on the stock. Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday, March 2nd. BTIG Research dropped their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a research report on Thursday, February 26th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $110.00 price target on the stock. Finally, Piper Sandler boosted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $118.10.

Kymera Therapeutics Stock Down 1.1%

Shares of NASDAQ KYMR opened at $82.71 on Wednesday. Kymera Therapeutics has a fifty-two week low of $28.06 and a fifty-two week high of $103.00. The firm's 50-day simple moving average is $84.42 and its 200 day simple moving average is $76.61. The stock has a market cap of $6.80 billion, a P/E ratio of -23.17 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. During the same period in the previous year, the business earned ($0.82) earnings per share. The company's revenue was up 55.5% on a year-over-year basis. On average, sell-side analysts anticipate that Kymera Therapeutics will post -3.35 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,576 shares of Kymera Therapeutics stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $673,733.68. Following the transaction, the chief financial officer owned 237,483 shares of the company's stock, valued at approximately $21,119,363.19. This trade represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. This represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 380,734 shares of company stock worth $32,193,902 in the last three months. Insiders own 16.01% of the company's stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC increased its stake in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter. Bessemer Group Inc. increased its stake in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics in the 4th quarter worth about $63,000.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.